文献速递水电解质与酸碱

2024年低钠血症治疗标准

Hyponatraemia-treatment standard 2024.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

低钠血症是住院患者最常见的电解质紊乱,与发病率、死亡率、住院时间和经济负担增加相关。使用3%氯化钠以100-150ml静脉推注或持续输注的纠正速度取决于症状的严重性和持续性,需要频繁生化监测。对于有症状的低钠血症,首选快速间歇给予高渗盐水;对于无症状轻度低钠血症,首选充足溶质摄入并初始限水500ml/天,根据血钠水平调整。几乎一半的SIADH患者对限水作为一线治疗无反应,目前尿素和托伐普坦被认为是SIADH最有效的二线治疗,但缺乏指导二线治疗选择的证据。

要点

  • 有症状低钠血症首选快速间歇给予高渗盐水,需频繁生化监测。
  • 无症状轻度低钠血症首选充足溶质摄入和初始限水500ml/天,根据血钠调整。
  • SIADH患者近半数对限水无反应,尿素和托伐普坦为最有效二线治疗。

核心结论

  • 有症状低钠血症首选快速间歇给予高渗盐水,无症状轻度者首选充足溶质摄入和限水。
  • SIADH患者近半数对限水无反应,尿素和托伐普坦为最有效二线治疗,但缺乏选择证据。
  • 根据指南,逐渐纠正和临床评估优于快速将血钠正常化至实验室参考范围。

研究设计与样本

  • 本文为2024年低钠血症治疗标准,基于指南和现有证据总结治疗推荐。

主要发现

  • 低钠血症是住院患者最常见的电解质紊乱,与发病率、死亡率、住院时间和经济负担增加相关。
  • 3%氯化钠以100-150ml静脉推注或持续输注的纠正速度取决于症状严重性和持续性。
  • 几乎一半的SIADH患者对限水作为一线治疗无反应。
  • 目前尿素和托伐普坦被认为是SIADH最有效的二线治疗,但缺乏指导二线治疗选择的证据。
  • 口服尿素被认为是非常有效且安全的治疗。

关键数值与推荐

  • 有症状低钠血症:首选快速间歇给予高渗盐水。
  • 无症状轻度低钠血症:充足溶质摄入(盐和蛋白质)和初始限水500ml/天,根据血钠水平调整。
  • SIADH二线治疗:尿素和托伐普坦被认为最有效。
  • 特定治疗可考虑用于高ADH活性的等容量或高容量患者(如伐普坦类)。
  • 根据指南,逐渐纠正和临床评估优于快速将血钠正常化至实验室参考范围。

临床怎么用

  • 有症状低钠血症应快速间歇给予高渗盐水,并频繁监测血钠。
  • 无症状轻度低钠血症应保证充足溶质摄入并初始限水500ml/天,根据血钠调整。
  • SIADH患者限水无效时,可考虑尿素或托伐普坦作为二线治疗。
  • 治疗过程中需密切监测,并准备给予低渗液体或去氨加压素以应对过度纠正。

局限性

  • 缺乏指导低钠血症二线治疗选择的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyponatraemia is the most common electrolyte disorder in hospital patients associated with increased morbidity, mortality, hospital stay and financial burden. The speed of a correction with 3% sodium chloride as a 100- to 150-ml intravenous bolus or continuous infusion depends on the severity and persistence of the symptoms and needs frequent biochemical monitoring. The rapid intermittent administration of hypertonic saline is preferred for treatment of symptomatic hyponatraemia. In asymptomatic mild hyponatraemia, an adequate solute intake with an initial fluid restriction (FR) of 500 ml/day adjusted according to the serum sodium (sNa) levels is preferred. Almost half of the syndrome of inappropriate antidiuretic hormone (SIADH) patients do not respond to FR as first-line therapy. At present, urea and tolvaptan are considered the most effective second-line therapies in SIADH. However, the evidence for guidance on the choice of second-line therapy of hypotonic hyponatraemia is lacking. Oral urea is considered to be a very effective and safe treatment. Mild and asymptomatic hyponatraemia is treated with adequate solute intake (salt and protein) and initial FR with adjustments based on sNa levels. Specific treatment with vaptans may be considered in either euvolaemic or hypervolaemic patients with high ADH activity. In order to ensure optimal patient outcome, close monitoring and readiness for administration of either hypotonic fluids or desmopressin may be crucial in the decision-making process for specific treatment and eventual overcorrection consequences. According to the guidelines, gradual correction and clinical evaluation is preferable over rapid normalization of sNa towards the laboratory reference ranges.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Spasovski G. Hyponatraemia-treatment standard 2024. Nephrol Dial Transplant. 2024. PMID: 39009016. doi:10.1093/ndt/gfae162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。